Carbohydrate Count Aided by a Simulation in People With Type 1 Diabetes Mellitus. A Protocol for a Clinical Trial

Carbohydrate Count Aided by a Simulation of Postprandial Glucose Dynamics Generated by a Mathematical Model in People With Type 1 Diabetes Mellitus. A Protocol for a Clinical Trial

Insulin remains the only approved treatment for type 1 diabetes mellitus patients and is used by many with type 2 diabetes. Carbohydrate counting is the most recommended way to prescribe prandial insulin dose because it is safe and efficacious, and also it allows a more variate diet to patients. Methods to improve carbohydrate counting include automatization of the process, optimizing carbohydrate meal content estimation, and including other nutrients such as fat into the equation. Being an iterative process that patients perfect by practicing and repeating, we believe that using simulations can improve carbohydrate counting. Simulations allow individuals to practice in a safe environment and help build confidence in one's ability to perform a task. In this clinical trial, patients assigned to the intervention group will have installed the STUDIA app, an automatic carbohydrate counter coupled to a mathematical model that simulates glucose excursions at the individual level using the patients' parameters in their smartphone. Time in range will be measured using a continuous glucose monitor.

Study Overview

• Status: Not yet recruiting
• Conditions: Diabetes Mellitus, Type 1
• Intervention / Treatment: Behavioral: STUDIA app

Detailed Description

Study setting Patients with T1DM trained in carbohydrate counting whose follow-up is considered feasible will be recruited from university hospitals and clinics dedicated to treating people with DM in the city of Medellín, Colombia.

Cointerventions Since only patients with T1DM will be recruited, patients in both groups are expected to be treated with insulin, either with a multiple injection scheme or an insulin pump. There are no other approved interventions for the treatment of T1DM. Researchers will be instructed to avoid the use of unapproved drugs for T1DM.

Protocol discontinuation

The protocol will be discontinued if any of the following conditions are met:

The patient does not wish to continue participating in the study. The patient's treating physician decides that she should not continue in the study due to the need for additional therapies that could affect the patient's ability to interact with the application or substantially modify glucose behavior and require other interventions, such as treatment with high doses of glucocorticoids.

The patient requires hospital treatment for more than 72 hours, and the use of the application at the researcher's discretion may interfere with her care or put her health at risk.

The patient develops a condition that contraindicates continuous glucose monitoring, such as intractable allergies to adhesives, frequent radiological evaluations that could contraindicate the implantation of devices, or any generalized skin condition that makes it impossible to insert the device in any area of the body.

Sample size The sample size has been calculated based on the primary outcome, i.e., the expected difference in the TIR.

Twenty-eight patients, 14 per group, will be required to analyze time in range using a mixed-effects model assuming a standard deviation of 4%, the statistical power of 90%, a type I error rate of 0.05%, and intra-subject variability of 5%, and inter-subject variability of 9%. The sample size was adjusted to 15 patients per group to admit a withdrawal rate of 10% in the intervention group, assuming that no patients in the control group could access the intervention. To maintain statistical power, sample size was adjusted by a factor that represents the retirement ratio.

Recruitment Participants will be recruited from University Hospitals and clinics specializing in the treatment of T1DM, to which patients are referred for treatment with an insulin pump or CGM support in Medellín, Colombia. Participants will be invited to the study by their treating physicians at each site.

Random sequence generation Participants will be randomly assigned in a 1: 1 ratio to the intervention or control group by a sequence of computer-generated random numbers, using permuted blocks of 4 to 6 individuals of variable size. The size of the blocks will not be revealed to ensure the concealment of the sequence. The sequence will be generated using a web application.

Allocation concealment mechanism Allocation concealment will be maintained using a web-based central randomization system. This system will not deliver the allocation code to a coordinator until after the last evaluation visit, preventing the researcher from knowing the group in which the patient will be included.

Random sequence implementation During the study, randomization will be implemented by the Pablo Tobón Uribe hospital research unit. The study coordinator will access the sequence list and assign the generated code to each patient. Within the application, the codes and the assignment of each code to one of the arms of the study will be prerecorded. Doing so will ensure the independence of the researchers and those responsible for data analysis.

Blinding Due to the nature of the intervention, patients and investigators will not be blinded. Instead, those responsible for data analysis will be blinded until the data analysis is complete. This will be done by assigning codes to the patients with whom those in charge of processing the data will identify each data set and build the databases. The assignment groups will be named Group A and Group B, and the intervention of each group will be known only to the coordinator in the research unit. The groups will be declassified for interpretation once the study is finished and the analysis plan is complete.

Data collection methods

The data will be collected using the code assigned to each patient during the generation of the randomization sequence, and the databases will be built weekly with the following information:

Time in range and time out of range: The time in range and out of range will be calculated from the data obtained from the continuous glucose monitor at each weekly visit by one of the investigators. This person will be trained in retrieving the data from the CGM.

Grade 3 hypoglycemic episodes: At each visit, one of the investigators will inquire and record the Grade 3 hypoglycemic episodes that the patient has presented.

Glycemic variability: The glycemic variability will be calculated based on the data obtained from the CGM.

Degree of agreement of the phenomenological-based model: The data to estimate the degree of agreement in the glucose levels of the phenomenological-based model will be obtained by comparing the simulation given by the model and the data obtained by the CGM. The glucose values estimated by the model will be stored on a server for the duration of the study and will later be entered into a database for analysis.

Actions carried out by the participants: The decision entered by the patient is reported in the same application that performs the carbohydrate count and stored on a server for later analysis.

Usability of the application: The participants will fill out the usability scale during the last visit. This data will be stored on a server and subsequently analyzed.

Figure 2 shows the patient's flowchart.

Retention Given the short follow-up time, no losses are expected. However, all reasonable efforts will be made to ensure follow-ups. The next visit will be scheduled at each follow-up visit, and the participants will be reimbursed for transportation costs if required to attend the visits.

Participants may leave the study at any time and for any reason. In addition, researchers may withdraw participants if they consider any danger to the participant continuing in the study.

Participants may be withdrawn from the study if the competent authority decides to do so.

Data management All data will be recorded electronically in forms stored on a virtual server during the study. Access to these forms will be restricted and only authorized by the Pablo Tobón Uribe Hospital research unit.

The data obtained from the CGM will be stored in its original format on a virtual server once the patient has been de-identified and can be accessed for data quality verification reasons.

Pablo Tobón Uribe Hospital's research unit will store all data indefinitely, but any information that could identify the patients will be deleted.

Statistical methods Table 1 shows the initial variables of the groups contained in the table for the operative definition of variables (Supplementary Table1) and will be presented as divided by the treatment assignment groups. The normality analysis will be performed using a Q-Q (quantile-quantile) graph and the Shapiro-Wilk test. According to data distribution, continuous variables will be presented as mean and standard deviation or medians and interquartile ranges. Discrete variables will be presented as medians and interquartile ranges, and qualitative variables will be presented as absolute frequencies and proportions.

Analysis population Complete analysis set: The full analysis set will consist of all randomized individuals, including follow-up and protocol deviation losses.

Per-protocol analysis set: The per-protocol analysis set will be made up of individuals who use the CHOC + Sim application at least 80% of the time. This proportion of the use of the simulation is proposed based on previous results that show that CGM sensor wear time is associated with greater reductions in glucose levels.

Objectives analysis plan A complete analysis set will be used for the primary endpoint and intention-to-treat analysis. This will be compared with the analysis result as a sensitivity analysis, taking into account only the set of per-protocol analyses. A mixed model analysis will be used to evaluate the time in range difference. The TIR is included as the dependent variable in the mixed-effects model analysis. The type of treatment and the time since randomization are included as independent variables. The TIR before randomization, type of insulin treatment, and pre-randomization HbA1c will be included as covariates.

The secondary counting outcomes will be analyzed in the per-protocol set. The number of episodes of Grade 3 hypoglycemia and number of DKA or HSS will be compared in both groups using a ratio of incidence rates, calculated using a Poisson regression if the variance is less than the mean or by negative binomial regression otherwise (60, 61).

Agreement between the phenomenological-based model and CGM measurements will be analyzed using limits of agreement (LoA) in the complete data set. However, the clinical interpretation of LoA is not straightforward without a minimal clinically significant difference. More importantly, it does not consider the clinical risk derived from an error in the estimation. Therefore, the authors also decided to perform an error grid analysis.

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Carlos E. Builes-Montaño, MD; Phone Number: 573053385136; Email: cbuiles@hptu.org.co

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age: Adults 18 years old or older.
• T1DM with at least one year since diagnosis.
• Treatment with a multiple daily injection scheme or insulin pump.
• Trained in advance CHOC.
• Have an HbA1c above 7.5% and below 10% in the three months before the randomization.
• Be able to use a Smartphone app for carbohydrate counting.

Exclusion Criteria:

• A confirmation or possible diabetic gastroparesia.
• With a chronic renal disease and an estimated filtration rate of 65 ml/min/1.73m2 or less using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.
• Patients been treated with any other form of medication different from insulin for DM.
• Pregnant women.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention; Patients assigned to the intervention group will receive the STUDIA application on their mobile device, which has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.	Behavioral: STUDIA app; STUDIA application has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. . This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
Active Comparator: Control; The patients assigned to the control group will also receive the STUDIA application on their mobile devices. The insulin dose calculation process is the same as that described for the intervention group. However, the simulation results will be kept hidden from the patient.	Behavioral: STUDIA app; STUDIA application has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. . This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
TIme in range	Time in range (TIR) is expressed as the ratio between the number of hours a patient spends in a given glucose range and the total number of hours of monitoring. According to the proposal of the international consensus of time in range (50) for people with usual hypoglycemia risk, it was defined for the study as the time between 70 and 180 mg / dL.	4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hyperglycemic crisis:	To define an episode of DKA or HSS, the definition proposed by the American Diabetes Association will be followed.	4 weeks
Hypoglycemia	Hypoglycemia will be defined according to the recommendations made by the American Diabetes Association and the European Association for the Study of Diabetes and the International Consensus for the use of the CGM, as episodes longer than 15 minutes as follows: Grade 1 hypoglycemia: A glucose value less than 70 mg / dL Grade 2 hypoglycemia: A glucose value less than 54 mg / dL Grade 3 hypoglycemia: Any glucose value that produces sufficient cognitive impairment to require the assistance of a third party.	4 weeks
Prediction capacity of the model of postprandial glucose values	A Bland and Altman graph will be used to estimate the agreement between the estimates made by the model and the glucose measured by the CGM. To incorporate the clinical significance of a possible glucose measurement error, a consensus has developed an error grid recommended for evaluating the clinical risk associated with a glucose measurement method. This same principle can be used to estimate the clinical risk associated with a simulation if it is used to aid decision-making. Therefore, it is proposed to evaluate the potential clinical risk derived from the disagreement between the measurement and the prediction using the error grid.	4 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Glycemic variability:	As a measure of glycemic variability, the coefficient of variation of glycemia in the 28 days of measurements will be used and described in both groups.	4 weeks
Usability of the application	At the end of the study, the Usability Scale of a System will be applied. This scale consists of 10 questions, each of which can be scored from 1 to 5, where one is total disagreement and five complete agreement. Despite its simplicity, it has been widely used to measure the usability of applications, systems, and objects, and it has been adapted to Spanish	4 weeks
Actions carried out by participants	To measure the actions carried out by users of the application, it will contain a survey of 4 questions to be answered after each calculation. The action taken by the individual will be evaluated. Change in insulin dose, change in planned meal amount, both or neither	4 weeks

Collaborators and Investigators

• Sponsor: Hospital Pablo Tobón Uribe
• Collaborators: Universidad de Antioquia
• Investigators: Principal Investigator: Carlos E. Builes-Montaño, MD, Hospital Pablo Tobon Uribe

Study record dates

Study Major Dates

• Study Start (Estimated): May 1, 2024
• Primary Completion (Estimated): May 1, 2024
• Study Completion (Estimated): August 1, 2024

Study Registration Dates

• First Submitted: December 20, 2021
• First Submitted That Met QC Criteria: December 20, 2021
• First Posted (Actual): January 10, 2022

Study Record Updates

• Last Update Posted (Estimated): March 5, 2024
• Last Update Submitted That Met QC Criteria: March 1, 2024
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1
• Other Study ID Numbers: 2021.004

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: The datasets generated or analyzed during the current study may be available from the sponsor institution on reasonable request.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No